Welcome to our dedicated page for TherapeuticsMD SEC filings (Ticker: TXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TherapeuticsMD, Inc. filings document the reporting obligations of a Nevada corporation with Nasdaq-listed common stock and a pharmaceutical royalty business. Current reports on Form 8-K furnish financial results and Regulation FD disclosures tied to license revenue, continuing operations, and the company’s royalty-based operating model.
The company’s proxy materials and related 8-K filings cover annual meeting matters, director elections, advisory compensation votes, auditor ratification, amendments affecting authorized common stock, and vote results. Other filings include auditor-change disclosures, late-filing notices, and formal records addressing governance, reporting controls, capital structure, and public-company compliance.
TherapeuticsMD, Inc. (TXMD) now operates as a pharmaceutical royalty company, collecting royalties on women’s health products such as IMVEXXY, BIJUVA, ANNOVERA and prenatal vitamins licensed to Mayne Pharma and others. For the six months ended June 30, 2026, license revenue from these agreements was $1.6 million, up from $1.3 million in 2025, and the company reported net income of $0.3 million versus a prior-year loss.
Operating expenses declined modestly to $3.1 million, helped by lower professional fees and smaller patent write‑offs, while other income of $1.8 million (including sublease income and interest) supported profitability. Cash and cash equivalents were $9.2 million and total assets $37.5 million, against total liabilities of $10.4 million, leaving stockholders’ equity at $27.1 million as of June 30, 2026.
The company discloses that its primary revenue comes from a concentrated set of licensees, including Mayne Pharma, Theramex and Knight, with royalty receivables totaling $16.0 million current and long term. Management states that uncertainties around royalty performance, working capital true‑ups and related disputes with Mayne Pharma, access to future financing and broader capital market conditions raise substantial doubt about its ability to continue as a going concern over the next 12 months. No adjustments have been made to the financial statements for this uncertainty.
TherapeuticsMD, Inc. reported its financial results for the quarter ended June 30, 2026 and furnished them in a press release. The business now operates as a pharmaceutical royalty company, primarily collecting royalties from licensees, and has exited research, development, and commercial operations.
The company states that it is evaluating potential strategic alternatives, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions. It highlights multiple risk factors, including reliance on licensees to commercialize products, reimbursement and regulatory uncertainties, Nasdaq listing risk, management transitions, intellectual property and competitive pressures, and a disclosed risk regarding the company’s ability to continue as a going concern.
Baselake Partners, LP, together with Baselake Management, LLC and David Paolella, reports beneficial ownership of common stock of TherapeuticsMD, Inc. This amendment states that the reporting group may be deemed to beneficially own 790,703 shares of common stock, representing 6.8% of the class.
The shares are held directly by Baselake Partners, LP, with Baselake Management, LLC acting as investment manager and David Paolella as managing member. All three reporting persons have shared voting and dispositive power over these shares and no sole voting or dispositive power. The ownership percentage is based on 11,574,362 shares outstanding as of May 11, 2026, as referenced from TherapeuticsMD's quarterly report. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
TherapeuticsMD, Inc. furnished an update on its business by issuing a press release with financial results for the three months ended March 31, 2026. The company now operates as a pharmaceutical royalty business, primarily collecting royalties from licensees instead of running its own research, development, or commercial operations.
The press release also discusses an ongoing evaluation of potential strategic alternatives, which may include transactions such as an acquisition, merger, sale of assets, or other business combinations. Extensive forward-looking statement language highlights uncertainties around royalty revenues, operating wind-down, Nasdaq listing status, and the company’s ability to continue as a going concern.
TherapeuticsMD, Inc. Schedule 13G reports that Baselake Partners, LP (with related reporting persons) beneficially holds 607,181 shares of Common Stock, representing 5.2% of the class.
Shares outstanding were 11,574,362 as of March 30, 2026, and the filings state shared voting and dispositive power through Baselake Management, LLC and David Paolella.
TherapeuticsMD, Inc. notified the SEC that it could not timely file its Form 10-K for the year ended December 31, 2025 due to an inadvertent printer error that omitted the predecessor auditor's report. The Company corrected the printing, filed a version on March 30, 2026 that lacked the auditor report, and subsequently submitted the 2025 Form 10-K on April 1, 2026 within the relief period provided by Rule 12b-25.
TherapeuticsMD, Inc. filed a report describing that it has released its financial results for the full year ended December 31, 2025, via a press release furnished as an exhibit. The company now operates as a pharmaceutical royalty business and no longer conducts research, development, or commercial operations.
The release references topics such as net loss, license revenues, operating expenses, balance sheet and an evaluation of potential strategic alternatives, and it includes extensive forward‑looking statement language highlighting risks around licensee performance, ongoing disputes, Nasdaq listing status, and the company’s ability to continue as a going concern.